Literature DB >> 28895064

A mouse model of HIV-associated neurocognitive disorders: a brain-behavior approach to discover disease mechanisms and novel treatments.

William R Tyor1,2, Heather Bimonte-Nelson3,4.   

Abstract

HIV-associated neurocognitive disorders (HAND) remain highly prevalent despite combined antiretroviral therapy (cART). Although the most common forms of HAND are mild and identified through neuropsychological testing, there is evidence that with aging these mild forms become more prevalent and may advance to the most severe form of HAND, HIV-associated dementia. Therefore, novel therapies must be developed that can be used adjunctively with cART to prevent deterioration or restore normal cognitive function. In order to develop innovative treatments, animal models are used for preclinical testing. Ideally, a HAND animal model should portray similar mild cognitive deficits that are found in humans. A mouse model of HAND is discussed, which demonstrates mild behavioral deficits and has been used to investigate cART and novel treatments for HAND. This model also shows correlations between abnormal mouse behavior due to HIV in the brain and pathological parameters such as gliosis and neuronal abnormalities. A recent advancement utilizes the object recognition test to monitor mouse behavior before and after treatment. It is postulated that this model is well suited for preclinical testing of novel therapies and provides correlations of mild cognitive impairment with pathological markers that can give further insight into the pathophysiology of HAND.

Entities:  

Keywords:  Animal model; HIV; Neurocognitive disorders

Mesh:

Year:  2017        PMID: 28895064      PMCID: PMC5845816          DOI: 10.1007/s13365-017-0572-6

Source DB:  PubMed          Journal:  J Neurovirol        ISSN: 1355-0284            Impact factor:   2.643


  25 in total

Review 1.  Humanized mouse models for HIV-1 infection of the CNS.

Authors:  Jenna B Honeycutt; Patricia A Sheridan; Glenn K Matsushima; J Victor Garcia
Journal:  J Neurovirol       Date:  2014-11-04       Impact factor: 2.643

2.  The recombinant vaccinia virus gene product, B18R, neutralizes interferon alpha and alleviates histopathological complications in an HIV encephalitis mouse model.

Authors:  Cari Fritz-French; Ramzi Shawahna; Jennifer E Ward; Leonard E Maroun; William R Tyor
Journal:  J Interferon Cytokine Res       Date:  2014-02-24       Impact factor: 2.607

3.  Combined antiretroviral therapy reduces brain viral load and pathological features of HIV encephalitis in a mouse model.

Authors:  Rajeth Koneru; M Foster Olive; William R Tyor
Journal:  J Neurovirol       Date:  2014-01-11       Impact factor: 2.643

4.  A new one-trial test for neurobiological studies of memory in rats. 1: Behavioral data.

Authors:  A Ennaceur; J Delacour
Journal:  Behav Brain Res       Date:  1988-11-01       Impact factor: 3.332

Review 5.  Requirements and selection of an animal model.

Authors:  M K Davidson; J R Lindsey; J K Davis
Journal:  Isr J Med Sci       Date:  1987-06

6.  HIV-associated neurocognitive disorders: Five new things.

Authors:  Jeffrey A Rumbaugh; William Tyor
Journal:  Neurol Clin Pract       Date:  2015-06

7.  The Janus kinase inhibitor ruxolitinib reduces HIV replication in human macrophages and ameliorates HIV encephalitis in a murine model.

Authors:  Woldeab B Haile; Christina Gavegnano; Sijia Tao; Yong Jiang; Raymond F Schinazi; William R Tyor
Journal:  Neurobiol Dis       Date:  2016-02-03       Impact factor: 5.996

8.  Highly active antiretroviral therapy and human immunodeficiency virus encephalitis.

Authors:  Jennifer E Cook; Somsankar Dasgupta; Lawrence D Middaugh; Elaine C Terry; Paul R Gorry; Steven L Wesselingh; William R Tyor
Journal:  Ann Neurol       Date:  2005-06       Impact factor: 10.422

9.  Asymptomatic HIV-associated neurocognitive impairment increases risk for symptomatic decline.

Authors:  Igor Grant; Donald R Franklin; Reena Deutsch; Steven P Woods; Florin Vaida; Ronald J Ellis; Scott L Letendre; Thomas D Marcotte; J H Atkinson; Ann C Collier; Christina M Marra; David B Clifford; Benjamin B Gelman; Justin C McArthur; Susan Morgello; David M Simpson; John A McCutchan; Ian Abramson; Anthony Gamst; Christine Fennema-Notestine; Davey M Smith; Robert K Heaton
Journal:  Neurology       Date:  2014-05-09       Impact factor: 9.910

10.  Clade C HIV-1 isolates circulating in Southern Africa exhibit a greater frequency of dicysteine motif-containing Tat variants than those in Southeast Asia and cause increased neurovirulence.

Authors:  Vasudev R Rao; Ujjwal Neogi; Joshua S Talboom; Ligia Padilla; Mustafizur Rahman; Cari Fritz-French; Sandra Gonzalez-Ramirez; Anjali Verma; Charles Wood; Ruth M Ruprecht; Udaykumar Ranga; Tasnim Azim; John Joska; Eliseo Eugenin; Anita Shet; Heather Bimonte-Nelson; William R Tyor; Vinayaka R Prasad
Journal:  Retrovirology       Date:  2013-06-08       Impact factor: 4.602

View more
  5 in total

1.  Optimizing animal models for HIV-associated CNS dysfunction and CNS reservoir research.

Authors:  Jeymohan Joseph
Journal:  J Neurovirol       Date:  2018-03-26       Impact factor: 2.643

2.  Novel method to quantify phenotypic markers of HIV-associated neurocognitive disorder in a murine SCID model.

Authors:  Christina Gavegnano; Woldeab Haile; Raj Koneru; Selwyn J Hurwitz; James J Kohler; William R Tyor; Raymond F Schinazi
Journal:  J Neurovirol       Date:  2020-09-08       Impact factor: 2.643

3.  Aging, comorbidities, and the importance of finding biomarkers for HIV-associated neurocognitive disorders.

Authors:  Jacqueline Rosenthal; William Tyor
Journal:  J Neurovirol       Date:  2019-03-13       Impact factor: 2.643

4.  Linked CSF reduction of phosphorylated tau and IL-8 in HIV associated neurocognitive disorder.

Authors:  Tugba Ozturk; Alexander Kollhoff; Albert M Anderson; J Christina Howell; David W Loring; Drenna Waldrop-Valverde; Donald Franklin; Scott Letendre; William R Tyor; William T Hu
Journal:  Sci Rep       Date:  2019-06-19       Impact factor: 4.379

5.  Baricitinib reverses HIV-associated neurocognitive disorders in a SCID mouse model and reservoir seeding in vitro.

Authors:  Christina Gavegnano; Woldeab B Haile; Selwyn Hurwitz; Sijia Tao; Yong Jiang; Raymond F Schinazi; William R Tyor
Journal:  J Neuroinflammation       Date:  2019-09-27       Impact factor: 8.322

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.